ILSI-Biomed Israel

Human Beta Cells Grown in a Culture

From BioMed Israel Week 2010: A Novel Therapeutic Method Based on the Ability of Stem Cells to Assist in Treating Juvenile Diabetes Will Replace the Insulin Injection Ramot, Tel Aviv University's technology transfer company, will present for the first time a therapeutic approach based on stem cells capability to assist in the treatment of juvenile diabetes, in the Israel BioMed Week 2010, which will be held on the 14th-16th of June in Tel Aviv. The main novelty of the treatment is a br...

Startup Weekly: ProtAb – Antibodies Against Arthritis

ProtAb is a company dedicated to eveloping an antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn's Disease, and has recently raised $4 million. Name: ProtAb CEO: Shira Yair Sector: Biopharma Medical Field: Autoimmune Diseases Est.: 2005 Stage: Late stage pre-clinical, after series A funding Vision: To develop a novel therapeutics for autoimmune diseases, based on the induction of natural anti-inflammatory mechanisms existing in...

Networking with Five Italian Companies

Five Italian biomedical companies are coming to Israel, and are interested in meeting suitable Israeli business partners It’s not WHAT you know, it’s WHO you know! Relationships are the catalyst for success! Do the above two statements look familiar? They should. They are the axioms of the Networking Theory (name not trademarked, invented on the spot). While networking seems to be the new religion of the business folks, I daresay that it’s been around for quite a bit. Even apes have...

A Novel Artificial Pancreas System

An aritifical pancreas system that maintains near-normal glucose levels by injecting both insulin and glucagon was succesfully demonstrated on a small number of patients An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin an...

Antioxidants Cause Genetic Abnormalities?

A new research reveals that high doses of antioxidants cause stem cells to develop genetic abnormalities, paving the way for cancer When people look back on the beginning of the 21st century, they might think this was the time of the antioxidants. Antioxidants supplements are being sold everywhere, usually without a doctor prescription, as a way to halt aging, heart diseases and whatever else is promised on the label. But current research, published online in the medical journal Stem Cells, r...

Plastics that Distort DNA Readings

A new research reveals that polypropylene tubes can contaminate solutions in the PCR and distort the DNA spectrometer readings. One year ago, a group of researchers at Hadassah-Hebrew University Medical Center in Jerusalem reported a sharp rise in the diagnoses of a certain metabolic disorder. To those of us who live in Jerusalem, fear not. Other than the Holyland story, nothing really happened in the Israeli capital in the last year. The only change is that the lab at Hadassah changed th...

3-6 May: Bio International Convention in Chicago

On May 3rd to 6th, the global event for biotechnology will go open in Chicago, with more than 1,700 exhibitions, and a strong Israeli presence. To the Conference Site Schedule of Events Bio- International Convention 2010 May 3rd – 6th Companies exhibiting and holding meetings at the Israel national pavilion. Booth #2548 Monday, May 3rd AICC LSPG Mission Breakfast Event, Brinks Hofer Gilson & Lione, NBC Tower, Suite 3600 455 North Cityfront Plaza Drive, 7:00 – 10:30 AM Tuesday, M...

First worldwide patients treated with anti-adhesion SpineShield

Magen Medical Solutions Ltd., a medical device company developing unique anti-adhesion devices for orthopedic applications, is pleased to announce that it has successfully implanted its first product, the SpineShield, in three patients at a clinical site in Europe. Post-operative adhesion is considered a major cause of failed back surgery. In up to 15% of cases, patients suffer from pain due to spinal adhesion, or scar tissue formation around the spinal cord, which may require a second su...

Avraham Pharmaceuticals: $9 M Funding for a Multy-functional Alzheimer drug

Avraham Pharmaceuticals Ltd. has raised $9 million from Yissum Research Development Company (the technology transfer arm of the Hebrew University of Jerusalem), Pontifax, Clal Biotechnology Industries (CBI), Professor Marta Weinstock-Rosin and others.   Yissum has announced that, together with the Technion Research and Development Foundation (TRDF), the technology transfer arm of the Technion Israel Institute of Technology, it will exclusively license to Avraham the commercial rights of La...

Meet the Speakers: The Future of siRNA

siRNA is one of the molecules of future medicine, with some success at early clinical trials. How will this molecule affect the future of therapeutics? Twelve years ago, a novel mechanism for shutting down genes has been described in a nature paper. The mechanism described made use of molecules called siRNA – Small Inhibitory RNA – whose potential for the development of new therapies for diseases like cancer has been recognized immediately. Last year, Dr. Dan Peer managed to create lip...